Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee
Curative Biotechnology (OTC: CUBT) announced that Marc Drimer, CPA, has joined its Board of Directors as an independent director and Chairman of the Audit Committee.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Curative Biotechnology (OTC: CUBT) announced that Marc Drimer, CPA, has joined its Board of Directors as an independent director and Chairman of the Audit Committee. With over 35 years of experience in corporate governance and finance, Drimer has had significant roles in international firms. His expertise includes financial operations and managing public offerings. Chairman Paul M. Michaels noted that Drimer's addition marks a vital milestone for the company as it seeks to explore capital market opportunities and advance its therapeutic pipeline aimed at rare diseases.
Positive
- Marc Drimer brings over 35 years of experience in corporate governance and financial services, enhancing the board's expertise.
- His role as Chairman of the Audit Committee improves oversight and compliance within the company.
- Drimer's background in managing public offerings may lead to stronger capital market strategies.
Negative
- Curative Biotechnology is currently not generating revenues, posing a risk to financial stability.
- Reliance on forward-looking statements highlights uncertainties that may impact actual results.
Details
News Market Reaction – CUBT
The recorded move for CUBT in the trading session of this news was -7.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rare diseases, announced today that Marc Drimer, CPA has joined its Board of Directors as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35 years of experience in all areas of corporate governance, compliance and operations in the financial services industry. He has held management positions in London and Geneva serving as Controller of Hertz Europe and Allied Maintenance. He is a graduate of Brooklyn College with a BS in Accounting and holds an MBA in Finance from New York University Graduate School of Business.
Mr. Drimer is currently the CFO for Lampert Capital Markets, Inc. responsible for all financial and operational aspects of the firm. He is the Financial and Operations principal as well as the Options and Municipal Bond principal. He has acted in a principal capacity as both a CEO and CFO for a number of brokerage firms and investment banks, responsible for the origination and syndication of numerous private placements and initial public offerings in a broad range of industries. He holds the Series 4, 7, 24, 27, 53, 63 and 79 licenses.
Chairman and President Paul M. Michaels said “Adding Marc Drimer to our Board as an independent director is another major milestone for Curative Biotech. Marc has decades of broad experience at the highest levels in the financial services industry and is known for his professionalism and business acumen. We are excited and eager to begin working with Marc in developing capital market options and potential partnerships as the Company advances its therapeutic pipeline.”
About Curative Biotechnology, Inc. http://CurativeBiotech.com
Curative Biotechnology is a development stage biomedical company focusing on novel treatments for rare diseases. Curative Biotech is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a clinical product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
SOURCE: Curative Biotechnology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.